Investigational drugs for hepatitis C.
作者： Robert Flisiak , Anna Parfieniuk
DOI: 10.1517/13543780903431034
关键词:
摘要: Importance of the field: Hepatitis C virus (HCV) infection affects 180 million people worldwide. Standard anti-HCV therapy combines effect pegylated IFN-alpha on immune response and antiviral activity ribavirin. Sustained virological rate achieved with this standard care medication is around 50% for HCV genotype 1, most prevalent worldwide genotype. So there an obvious need to enhance efficacy treatment.Areas covered in review: We describe novel treatment options studied within recent few years, which are focused inhibitors HCV-specific enzymes such as NS3/4 protease NS5B polymerase or influence host-virus interactions.What reader will gain: According data, triple therapies consisted interferons, ribavirin demonstrate significant improvement comparison current medication. Moreover, new forms interferons ribavirin, more effective, less toxic, mor...
informahealthcare.com参考文章(61)
Mark S. Sulkowski, Louis R. Lambiase, G. Mani Subramanian, Vijayan Balan, David R. Nelson, Gregory T. Everson, Rolland C. Dickson, Rusell H. Wiesner, Paul A. Moore, Andy Garcia, Ren Yu, Modulation of interferon-specific gene expression by albumin-interferon-α in interferon -α-experienced patients with chronic hepatitis C Antiviral Therapy. ,vol. 11, pp. 901- 908 ,(2006)
Kazuaki Inoue, Kazuhiko Sekiyama, Masaya Yamada, Tsunamasa Watanabe, Hiroshi Yasuda, Makoto Yoshiba, Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial Journal of Gastroenterology. ,vol. 38, pp. 567- 572 ,(2003) , 10.1007/S00535-002-1104-5
Philip Hilgard, Alisan Kahraman, Nils Lehmann, Cornelia Seltmann, Susanne Beckebaum, R Stefan Ross, Hideo A Baba, Massimo Malago, Christoph E Broelsch, Guido Gerken, Cyclosporineversustacrolimus in patients with HCV infection after liver transplantation: Effects on virus replication and recurrent hepatitis World Journal of Gastroenterology. ,vol. 12, pp. 697- 702 ,(2006) , 10.3748/WJG.V12.I5.697
X TONG, R CHASE, A SKELTON, T CHEN, J WRIGHTMINOGUE, B MALCOLM, Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Research. ,vol. 70, pp. 28- 38 ,(2006) , 10.1016/J.ANTIVIRAL.2005.12.003
F. Poordad, E. Lawitz, R. Pozza, M. Shiffman, B. Bacon, E. Godofsky, D. Halliman, J. Heise, E. Chun, J. Hammond, 14 EFFICACY AND SAFETY OF WEIGHT-BASED REGIMENS OF TARIBAVIRIN OR RIBAVIRIN, GIVEN WITH PEGINTERFERON ALFA-2B, AT 12 WEEKS AFTER TREATMENT (SVR12) IN NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC-HEPATITIS C Journal of Hepatology. ,vol. 50, ,(2009) , 10.1016/S0168-8278(09)60016-7
N. Forestier, D. Larrey, P. Marcellin, Y. Benhamou, D. Guyader, W. Bradford, S. Porter, A. Patat, R. Rouzier, S. Zeuzem, 85 ANTIVIRAL ACTIVITY AND SAFETY OF ITMN-191 IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) Journal of Hepatology. ,vol. 50, ,(2009) , 10.1016/S0168-8278(09)60087-8
E. Lawitz, R. Rouzier, T. Nguyen, M. Huang, J. Ke, J. Praestgaard, D. Serra, M. Koziel, T. Evans, 1045 SAFETY AND ANTIVIRAL EFFICACY OF 14 DAYS OF THE CYCOPHILIN INHIBITOR NIM811 IN COMBINATION WITH PEGYLATED INTERFERON α2a IN RELAPSED GENOTYPE 1 HCV INFECTED PATIENTS Journal of Hepatology. ,vol. 50, ,(2009) , 10.1016/S0168-8278(09)61047-3
Curtis Cooper, Eric J. Lawitz, Peter Ghali, Maribel Rodriguez-Torres, Frank H. Anderson, Samuel S. Lee, Jean Bédard, Nathalie Chauret, Roch Thibert, Isabel Boivin, Olivier Nicolas, Louise Proulx, Evaluation of VCH-759 monotherapy in hepatitis C infection Journal of Hepatology. ,vol. 51, pp. 39- 46 ,(2009) , 10.1016/J.JHEP.2009.03.015
Marina Berenguer, Victoria Aguilera, Martín Prieto, Fernando San Juan, José M. Rayón, Salvador Benlloch, Joaquín Berenguer, Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transplantation. ,vol. 12, pp. 762- 767 ,(2006) , 10.1002/LT.20655
Christophe Hézode, Nicole Forestier, Geoffrey Dusheiko, Peter Ferenci, Stanislas Pol, Tobias Goeser, Jean-Pierre Bronowicki, Marc Bourlière, Shahin Gharakhanian, Leif Bengtsson, Lindsay McNair, Shelley George, Tara Kieffer, Ann Kwong, Robert S. Kauffman, John Alam, Jean-Michel Pawlotsky, Stefan Zeuzem, Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. The New England Journal of Medicine. ,vol. 360, pp. 1839- 1850 ,(2009) , 10.1056/NEJMOA0807650